Satellite liver: Just WOW
How to scale it ?
It’s an elegant engineering design for acute liver dysfunction: injectable hydrogel microspheres combined with hepatocytes and supportive fibroblasts, designed to stay localized, integrate with host tissue, and become vascularized in vivo.
I’m currently thinking about the manufacturing process required to scale this technology.
It’s an exhilarating problem.
3 major scale-up challenges:
1. Cell sourcing
Where do the hepatocytes come from?
Patient-derived cells? Donor pools? iPSC-derived hepatocytes? Universal engineered cells?
Each route changes the CMC package, cost, logistics, immunology and GMP strategy.
2. Microsphere manufacturing
The microfluidic step is not a joke: producing uniform hydrogel microspheres at GMP scale, with controlled size distribution, mechanical properties, sterility and reproductibility.
3. Final formulation & delivery
You need to mix living hepatocytes, fibroblasts and microspheres without damaging the cells, while controlling viscosity, injectability, aggregation, dose uniformity and shelf life.
I have some processes idea but need to do the math and design.
Can we make satellite livers reproducible, scalable, GMP-ready and clinically deployable?
Don’t know but the science is exciting.
This is one stone toward the future of regenerative medicine.